通过近距离激活反应疗法开发共价蛋白药物
Qingke Li1, Qu Chen2, Paul C Klauser3
1Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong 510515, China; Hangzhou Research Institute of Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Hangzhou 310018, China.
研究人员开发了一种新的方法,通过将特殊的氨基酸纳入PD-1来制造共价蛋白质药物. 这使得它与PD-L1结合得不可逆转,在具有挑战性的疾病中具有强大的抗瘤作用.
科学领域:
- 生物化学
- 分子生物学
- 药物发现
背景情况:
- 对复杂疾病而言,共价药物比非共价药物具有治疗优势.
- 由于蛋白质固有的无法与标形成共价键,开发共价蛋白药物一直是具有挑战性的.
研究的目的:
- 引入一种新的近距离反应疗法 (PERx) 方法来产生共价蛋白药物.
- 设计人类编程细胞死亡蛋白-1 (PD-1) 以选择性地结合PD-L1.
主要方法:
- 利用遗传密码扩展将生物反应性氨基酸硫酸-L-氨酸 (FSY) 纳入PD-1.
- 在目标相互作用时,在PD- 1上显示FSY和PD- L1上的近位胺之间的选择性共价反应.
- 在免疫人化的小鼠中评估了工程共价PD-1 ((FSY) 的体外和体内疗效.
主要成果:
- 工程 PD-1 ((FSY) 实现了对 PD-L1 的选择性和不可逆转的结合.
- 与非共价性野生型PD-1相比,共价性PD-1 (FSY) 的抗瘤疗效显著提高.
- 相对应的PD- 1 (FSY) 的治疗效果与抗PD- L1抗体治疗相比或更高.
结论:
- PERx方法提供了一个多功能平台,可以从相互作用的蛋白质对中创建共价蛋白质结合剂.
- 这项技术可以针对特定的共价蛋白,为疾病开辟新的治疗途径.
- PERx技术克服了传统的非共价蛋白药物的局限性,提供了增强的治疗潜力.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11:09Constructing Thioether/Vinyl Sulfide-tethered Helical Peptides Via Photo-induced Thiol-ene/yne Hydrothiolation
Published on: August 1, 2018
相关概念视频
Drug-Receptor Bonds
In...
Protein-protein Interfaces
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Covalently Linked Protein Regulators
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
